Pliant Therapeutics Presents Positive INTEGRIS-PSC Trial Data at The Liver Meeting® 2024
Pliant Therapeutics presented clinical data on bexotegrast, showing positive effects in primary sclerosing cholangitis at AASLD 2024.Quiver AI SummaryPliant Therapeutics, Inc. announced the presentation...
Why Shares of Pliant Therapeutics Are Rising Tuesday
The company's lead therapy fared well in a phase 2a trial to treat two separate conditions.
Why Pliant Therapeutics Stock Is Skyrocketing This Week
The company's experimental idiopathic pulmonary fibrosis drug is showing a lot of promise.
Pliant Therapeutics zoomed 34% higher and added to that gain in the next session.This followed good news about clinical trials for a lung-condition treatment.
Pliant Therapeutics (NASDAQ: PLRX) Reports Positive Phase 2 Clinical Trial Data of Bexotegrast in Treatment of Idiopathic Pulmonary Fibrosis
Pliant Therapeutics, Inc. (NASDAQ: PLRX) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research and development